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Abstract 
Background: Hypertrophic cardiomyopathy (HCM) related myocardial vascular remodelling may lead to the reduc‑
tion of myocardial blood supply and a subsequent progressive loss of cardiac function. This process has been difficult 
to observe and thus their connection remains unclear. Here we used non‑invasive myocardial blood flow sensitive 
CMR to show an impairment of resting myocardial perfusion in a mouse model of naturally occurring HCM.
Methods: We used a mouse model (DBA/2 J; D2 mouse strain) that spontaneously carries variants in the two most 
susceptible HCM genes—Mybpc3 and Myh7 and bears the key features of human HCM. The C57BL/6 J (B6) was used 
as a reference strain. Mice with either B6 or D2 backgrounds (male: n = 4, female: n = 4) underwent cine‑CMR for func‑
tional assessment at 9.4 T. Left ventricular (LV) wall thickness was measured in end diastolic phase by cine‑CMR. Quan‑
titative myocardial perfusion maps (male: n = 5, female: n = 5 in each group) were acquired from arterial spin labelling 
(cine ASL‑CMR) at rest. Myocardial perfusion values were measured by delineating different regions of interest based 
on the LV segmentation model in the mid ventricle of the LV myocardium. Directly after the CMR, the mouse hearts 
were removed for histological assessments to confirm the incidence of myocardial interstitial fibrosis (n = 8 in each 
group) and small vessel remodelling such as vessel density (n = 6 in each group) and perivascular fibrosis (n = 8 in 
each group).
Results: LV hypertrophy was more pronounced in D2 than in B6 mice (male: D2 LV wall thickness = 1.3 ± 0.1 mm 
vs B6 LV wall thickness = 1.0 ± 0.0 mm, p < 0.001; female: D2 LV wall thickness = 1.0 ± 0.1 mm vs B6 LV wall thick‑
ness = 0.8 ± 0.1 mm, p < 0.01). The resting global myocardial perfusion (myocardial blood flow; MBF) was lower in D2 
than in B6 mice (end‑diastole: D2  MBFglobal = 7.5 ± 0.6 vs B6  MBFglobal = 9.3 ± 1.6 ml/g/min, p < 0.05; end‑systole: D2 
 MBFglobal = 6.6 ± 0.8 vs B6  MBFglobal = 8.2 ± 2.6 ml/g/min, p < 0.01). This myocardial microvascular dysfunction was 
observed and associated with a reduction in regional MBF, mainly in the interventricular septal and inferior areas 
of the myocardium. Immunofluorescence revealed a lower number of vessel densities in D2 than in B6 (D2 capil‑
lary = 31.0 ± 3.8% vs B6 capillary = 40.7 ± 4.6%, p < 0.05). Myocardial collagen volume fraction (CVF) was significantly 
higher in D2 LV versus B6 LV mice (D2 CVF = 3.7 ± 1.4% vs B6 CVF = 1.7 ± 0.7%, p < 0.01). Furthermore, a higher ratio of 
perivascular fibrosis (PFR) was found in D2 than in B6 mice (D2 PFR = 2.3 ± 1.0%, B6 PFR = 0.8 ± 0.4%, p < 0.01).
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Background
Hypertrophic cardiomyopathy (HCM) is the most preva-
lent cardiac genetic disease with an estimated population 
prevalence of HCM ranging from 1:200 to 1:500 indi-
viduals [1, 2] and mainly caused by distinct genetic vari-
ants in sarcomeric proteins. The major clinical feature of 
HCM is left ventricular (LV) hypertrophy (LVH), which is 
often asymmetric and preferentially affects the interven-
tricular septum, in the absence of any other conditions 
that could induce LVH, such as environmental factors 
(stress or physical activities), hypertension, or aortic 
stenosis [9]. Sudden cardiac death can be the first mani-
festation of HCM, particularly in young [3, 4] and asymp-
tomatic patients [5, 6]. The key sarcomere genes [7] 
most frequently affected genes in HCM are the cardiac 
myosin-binding protein C (MYBPC3) [8] and β-myosin-
heavy chain (MYH7) [9]. Aberrant proteins trigger myo-
cardial tissue remodelling which is a complex process of 
transcriptional, signaling, structural, electrophysiologi-
cal, and functional events occurring within the cardiac 
myocyte and myocardium [10]. The myocardial tissue 
remodelling contributes to small vessel disease (namely 
vascular remodelling), cardiac hypertrophy, myocyte 
disarray, myocardial fibrosis and ultimately compromise 
the cardiac function [11, 12]. While the early detection of 
myocardial remodelling is a key to effective disease man-
agement [13], at present no in  vivo imaging markers of 
dynamic changes of microvasculature have been found 
[14]. CMR can detect ventricular wall hypertrophy and 
fibrosis progression, two main features that are useful in 
predicting HCM prognoses [15], but monitoring those 
morphological changes on the macroscopic and meso-
scopic scales cannot detect subclinical microvascular 
dysfunctions, which potentially might be more sensitive 
markers of disease progression [16]. Here we focused 
on the remodelling of small vessels and microvascular 
dysfunction in the myocardium, which may lead to a 
reduction of myocardial blood supply and a subsequent 
progressive loss or deterioration of cardiac function. In 
response to varying physiological or pathological condi-
tions and functional demands, blood vessels are continu-
ously adapting their structural change [12].
Microvascular dysfunction in HCM patients has been 
proposed as a strong predictor of clinical outcomes 
and mortality risk [17], but the relationship between 
this and myocardial remodelling is poorly understood. 
The small vessels of the microvascular network supply 
the myocardium with oxygen to maintain functional 
cardiac tissue integrity [18]. Myocardial wall thicken-
ing connected to pressure overload is thought to play a 
role in impairing coronary inflow and trigger a progres-
sive ventricular dysfunction [19]. Hypertrophy-induced 
deficits in myocardial perfusion and micro-circulation 
might also trigger the pathological deposition of col-
lagen in the myocardium. This reduces myocardial 
blood flow and might be the key determinant of sub-
sequent heart failure [20]. This suggests that monitor-
ing changes in micro-perfusion might make an effective 
early indicator to diagnose the disease and have the 
chance to provide early procedures that improve blood 
flow.
Local myocardial blood volume and blood flow are 
important indicators of changes in micro-perfusion 
[21]. Recent work has investigated the relationship 
between hypertrophy and the myocardial microvas-
cular network in HCM [22]. In these studies, the frac-
tional tissue blood volume per cardiac tissue volume 
(Bvf ), defined as the volume in the microvascular net-
work, was directly probed by Bvf-sensitive CMR using 
blood oxygenation-weighted imaging contrast [22]. 
Myocardial regions with reduced Bvf were highly cor-
related with ventricular wall thickening [22, 23]. Yet the 
factors responsible for the reduction of microvascular 
network volume remain unknown.
We hypothesize that vascular dysregulation caused by 
hypertrophy or excessive collagen deposits may contrib-
ute to the microstructural changes in HCM and cause 
the reduction. Using a mouse model that closely reflects 
human HCM, we quantified the amount of blood deliv-
ered to myocardial tissue per unit time using myocar-
dial blood flow (MBF) CMR based on the labelling of 
arterial proton spins [24, 25]. Unlike widely used meth-
ods based on contrast agent enhanced first pass perfu-
sion CMR, arterial spin labelling (ASL)-CMR does not 
require an injection of exogenous contrast material, and 
thus can be repeated [26]. Employing this approach, the 
goal was to find any sign of small vessel change indicated 
by myocardial perfusion and then correlate the changes 
detectable by CMR with microstructural histology in the 
murine heart – something that is difficult to do in human 
patients. For this purpose MBF, capillary density, perivas-
cular fibrosis and interstitial fibrosis were determined.
Conclusions: Our work describes an imaging marker using cine ASL‑CMR with a potential to monitor vascular and 
myocardial remodelling in HCM.
Keywords: Hypertrophic cardiomyopathy (HCM), Myocardial remodelling, Microvascular dysfunction, Perfusion, 
Myocardial blood flow (MBF), Cardiac MRI (CMR), Arterial spin labelling (ASL)
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Methods
Mouse model carries HCM gene variants
All animal studies were approved by the Berlin State 
review board at the ‘’Landesamt für Gesundheit und Soz-
iales (LAGeSo; State Office for Health and Social Affairs 
Berlin)’’. Genetic variants that potentially cause myocar-
dial functional changes were previously reported [27]. 
We used a mouse model (DBA/2J; D2 mouse strain) that 
spontaneously carries variants in the two most suscep-
tible HCM genes—Mybpc3 and Myh7 and bears the key 
features of human HCM [28]. The C57BL/6J (B6) strain 
was used as reference. Mice were handled according to 
the LAGeSo and internal (MDC) rules and regulations. 
In total, 36 eight-month-old mice were used (4 male and 
4 female mice with B6 or D2 backgrounds were used for 
cardiac functional assessment and 5 male and 5 female 
mice with B6 or D2 were used for ASL-CMR). The exper-
imental design is illustrated in Fig. 1a.
Cardiovascular magnetic resonance imaging
Physiological control
All in  vivo CMR measurements were performed on a 
9.4 T small animal CMR system (Biospec 94/20, Bruker 
Biospin, Germany). Anesthesia of mice was induced 
using 3% isoflurane (CP-Pharma, Germany) in 500  mL/
min medical air and 500  mL/min oxygen and was 
maintained at 0.5 to 1.0% isoflurane after the induction. 
During CMR examinations, it was important to maintain 
hemodynamic stability to avoid confounding interfer-
ence with the imaging results. During cine ASL-CMR 
scans, oxygen was given at a dose of at least 800 mL/min 
to avoid hypoxia. Core body temperature was maintained 
at 36 ± 0.5 °C using a heated water tubing system. Heart 
rates, respiration rates and core body temperature were 
closely monitored using a remote monitoring system 
(Model 1025, SA Instruments Inc., Stony Brook,  New 
York, USA).
Cardiac physiological assessments
For the high-fidelity approaches for CMR in mice, 
image acquisition was conducted using a cryogeni-
cally-cooled radiofrequency (RF) transceiver antenna 
(CryoProbe, Bruker Biospin). To obtain a stack of car-
diac short axis (SAX) views covering the whole mouse 
heart, 9–10 slices were consecutively acquired using a 
self-gated bright-blood cine (IntraGate-FLASH, TR/
TE = 8.5/1.58 ms, FA = 20°, receiver bandwidth = 98 kHz, 
FOV = 11 × 22   mm2, matrix size = 192 × 384, slice 
thickness = 0.8  mm, with a temporal resolution of 16 
images per cardiac cycle [29]. Cardiac function assess-
ment was performed using cvi42 (Circle Cardiovascular 
Imaging, Calgary, Alberta, Canada) and analyzed on a 
Fig. 1 a Schematic representation of experimental design. b Schematic illustration of the tagging slice position used for quantifying myocardial 
blood flow (MBF) with arterial spin labelling (ASL)‑cardiovascular magnetic resonance (CMR). By labelling water molecules in the inflowing blood 
from coronary artery as tracers which then perfused into myocardium, labelled blood signal can be imaged in the mid‑left ventricle (LV). c Ten 
consecutive color coded short axis myocardial perfusion maps from a measurement series over one cardiac cycle
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slice-by-slice basis. Endo- and epi-cardiac borders were 
manually segmented in end-systole and end-diastole 
using a stack of SAX cine images. LV ejection fraction 
(LVEF) and myocardial mass (both in diastole and sys-
tole) were calculated. LV wall thickness was measured in 
end diastolic phase. Six SAX views were used for measur-
ing the maximal wall thickness.
Quantification of myocardial perfusion using cine ASL‑CMR 
(cineASL)
The cineASL technique used is described in detail else-
where [24, 30]. This cineASL approach was previously 
validated against a classical FAIR Look-Locker Gradient-
Echo technique under rest and stress conditions [30] and 
built upon a previously published version. The princi-
ple of ASL-CMR is to label the inflowing coronary arte-
rial blood as an endogenous diffusible tracer (Fig. 1b). It 
relies on an electrocardiographically (ECG)-gated cine 
Fast Low Angle Shot (cine-FLASH) technique repeated 
over several cardiac cycles for each line of k-space. In a 
preparation module, spin labelling using dedicated radio-
frequency pulses is applied to tag (by inverting the spins) 
the longitudinal magnetization of coronary blood water 
protons before it enters the imaging plane in the myocar-
dium [25]. The labelling pulses were produced by replac-
ing one cine readout within the cardiac cycle at the time 
of valve closure (end systole) by a hyperbolic secant adia-
batic inversion pulse. For labelling, a slice-selective inver-
sion slab was placed on the aortic root while another 
selective inversion slab was placed in the opposite direc-
tion below the imaging slice (as control labelling). Two 
cardiac gated (on ECG) mid-LV SAX cine image series 
were acquired under labeled and control conditions. For 
averaging, the acquisition was repeated 35 times over 
several cardiac cycles for labeled and control conditions 
without a delay, as described in the original version [30]. 
Provided that the magnetization of the inflowing blood 
is the only difference between the control and the label 
image, a difference map was calculated yielding perfu-
sion-weighted images of the heart for each cardiac cine 
phase, with the signal intensity being proportional to 
myocardial perfusion. For quantification of MBF, the 
acquisitions were done using a 72  mm inner diameter 
volume resonator (Bruker Biospin) for uniform RF trans-
mission in conjunction with a 4 channel cardiac RF array 
(Bruker Biospin) used for signal reception. The follow-
ing parameters were used for the cineASL technique 
[24]: TR/TE = 7.6/1.12  ms, FA = 6°, FOV = 25 ×  25mm2, 
matrix size = 128 × 64, slice thickness = 1  mm, temporal 
resolution within one cardiac cycle = 7.6 ms, 35 averaged 
cine blocks for both tag and control images. Throughout 
the ASL measurements, a two lead electrode was used to 
detect ECG signals of the mouse heart. The ECG trace 
was monitored with dedicated modules for small animals 
(SA Instruments Inc.). Image acquisition was gated upon 
detection of the ECG’s R-wave. Quantitative image analy-
sis and calculation of perfusion maps were performed 
using in-house developed analysis tools built in the Inter-
active Data Language (IDL). After averaging the steady-
state cine repetitions from successive cardiac cycles, 
regional perfusion was analyzed using a ventricular seg-
mentation model [31]. The border of each myocardial 
segment was manually delineated for mid-ventricular 
SAx slices obtained from end-diastolic and end-systolic 
cardiac phases. Mean MBF were then calculated for 
regions of interest defined by septal, lateral, anterior, and 
inferior traced endocardial and epicardial contours which 
are illustrated in Fig. 4a.
High resolution CMR of ex vivo heart
Following in vivo CMR, mice were perfused with 4% PFA. 
Fixed ex vivo hearts (n = 2 from each group for illustra-
tion) were imaged with high spatial resolution to check 
for the presence of myocardial hypertrophy and disar-
ray (RARE, TR/TE = 2200/40.7 ms, FOV = 15 × 10  mm2, 
matrix size = 500 × 336, slice thickness = 0.3  mm, in-
plane spatial resolution = 30 µm).
Histological assessment and microscopic image processing
Directly after the ASL-CMR scans, the mouse hearts 
were quickly removed from the chest and perfused with 
ice-cold cardioplegic solution (15 mM KCl in PBS). This 
step arrested the cardiac cycle during diastole. Heart tis-
sue were post fixed in 4% PFA solution and then dehy-
drated. Fixed hearts were either cryopreserved in a 
30% sucrose-PBS solution for at least 3  days at 4  °C or 
embedded with paraffin. Cryopreserved hearts were then 
embedded in OCT (Tissue-Tek, Sakura Finetek Ger-
many GmbH, Staufen im Breisgau, Germany), frozen on 
dry ice, and stored in − 80 °C until sectioning. For tissue 
sectioning, 10  µm cross-sections of hearts were cryo-
sectioned using a cryostat microtome (Leica CM3050S, 
Wetzlar, Germany) starting from the apex. Four µm par-
affin sections of heart were prepared using a microtome 
(Thermo Fischer HM355S, Fisher Scientific GmbH, 
Schwerte, Germany).
Fluorescent microscopy
For detecting myocardial microvasculature, heart sec-
tions were analyzed using immunofluorescence (IF) 
staining methods. Briefly, 10 µm cryo-preserved sections 
were mounted on glass slides. For blocking the unspe-
cific bindings, tissue sections were treated with a block-
ing solution containing 10% normal donkey serum (NDS; 
Sigma-Aldrich, Taufkirchen, Germany), 4% fetal bovine 
serum (BSA; Sigma-Aldrich, Germany), 0.2% Triton 
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X-100 in PBS for 3 h at room temperature. Heart tissue 
sections from entire mid-ventricular short-axis sections 
were then incubated with Alexa Fluor 488 conjugated 
Isolectin B4 (1:500; Invitrogen) diluted in 0.01  M PBS 
with 5% NDS over night at 4 °C. After washing in freshly 
prepared PBS with 2.5% NDS, the nuclei were stained 
with Hoechst 33,342 (Sigma-Aldrich). The presence of 
fluorescent stained cells was determined by observation 
on a microscope (BZ 9000 Keyence GmbH, Neu-Isen-
burg, Germany). Quantifications of Isolectin B4 + vessels 
were performed in 10 random fields captured under 200 
magnifications. All image processing was then performed 
using ImageJ (National Institutes of Health, Bethesda, 
Maryland, USA)  and Adobe Illustrator  (Adobe, San 
Jose, California, USA). The captured images were care-
fully screened. Blurred images were excluded from the 
quantification. For quantification, small vessel density in 
myocardium was analyzed using ImageJ software plugins 
(vessel density) in five random microscopic fields in the 
whole myocardium and expressed as percentage (the 
number of small vessels per square millimeter tissue).
Light microscopy
To determine the interstitial collagen (collagen volume 
fraction; CVF) [32] and perivascular collagen deposit 
(perivascular fibrosis ratio; PFR) [33] in the mouse heart, 
cryopreserved or rehydrated heart paraffin sections were 
stained in Sirius Red solution (detecting collagen) for 1 h 
at room temperature. Stained sections were rinsed twice 
in 1% acetic acid, dehydrated through serial concentra-
tions of ethanol washes, cleared in xylene, and mounted 
with a xylene based mounting medium. Extensive washes 
were performed between each step. Images were taken 
using a microscope (BZ-9000, Keyence Corporation of 
America, Itasca, Illinois, USA). CVF was determined as 
the percent of collagen-stained area/total myocardial 
area and quantified using ImageJ software. Excluding 
endocardial and perivascular collagen, the interstitial 
CVF (%) was calculated from the area stained by the 
Sirius red. PFR (%) was determined from all collagen sur-
rounding an intra-myocardial coronary artery and was 
calculated as the ratio of the fibrosis area surrounding the 
vessel to the total vessel area. For each sample, 5 micro-
scopic fields were examined.
Statistical analysis
All data analyses of the cardiac physiological measure-
ments using CMR and histopathology were performed by 
reviewers blinded to the mouse genetic makeup. Experi-
mental analysis and statistics were conducted in R studio 
(R Studio Inc., Boston, USA; http:// www. rstud io. com/) 
or GraphPad Prism 5 (GraphPad Software, La Jolla, Cali-
fornia, USA). The graphs were generated by GraphPad 
Prism 5. The comparison between B6 and D2 mice in 
diastolic and systolic cardiac phases were analyzed using 
one-way ANOVA. The sampling frequency was further 
tested for normality using Kolmogorov–Smirnov test. 
A low K-S statistic value represent with a high p-value 
indicate that data is normally distributed. Statistical dif-
ference of MBF by sex or cardiac phases between groups 
were further tested using factorial analysis of variance 
(Factorial ANOVA) followed by post-hoc Turkey HSD 
(Honestly Significant Difference). The Spearman’s rank 
correlation coefficient was used for testing the strength 
of the correlation between LV thickness and global MBF. 
Capillary density (%), CVF (%) and PFR (%) from B6 and 
D2 were compared using t-test followed by Mann Whit-
ney test. All data are presented as mean ± SD. The differ-
ences were considered statistically significant at *P < 0.05; 
**P < 0.01; and ***P < 0.001.
Results
Cardiac functional measurements in spontaneous HCM 
mouse model
LVH is a key phenotype of HCM. We evaluated the 
cardiac phenotype in mice carrying natural genetic 
variants in Mybpc3 and Myh7, which are the two most 
frequently mutated genes in human HCM [34]. In all 
mice groups, LV remodelling was not observed in B6 
control animals. D2 mice exhibited LVH when com-
pared to B6 reference strain (Fig.  2a). LVH was more 
pronounced in both male and female D2 mice than in 
B6 mice (male: D2 LV wall thickness = 1.3 ± 0.1  mm vs 
B6 LV wall thickness = 1.0 ± 0.03  mm, p < 0.001; female: 
D2 LV wall thickness = 1.0 ± 0.1 mm vs B6 LV wall thick-
ness = 0.8 ± 0.1 mm, p < 0.01) (Fig. 2b). LVEF in D2 mice 
remained normal and showed no significant difference 
when compared to B6 (male: D2 LVEF = 70.3 ± 5.8% vs 
B6 LVEF = 73.8 ± 0.7%; female: D2 LVEF = 71.9 ± 4.1%, vs 
B6 LVEF = 68.9 ± 5.5%; Fig. 2b).
Cine ASL‑CMR detection of myocardial perfusion deficit
We investigated non-invasively the impact of primary 
genetic variants on myocardial perfusion using MBF 
sensitive CMR. As previously shown, the cine ASL-
CMR sequence allows tracking of dynamic MBF changes 
across the entire cardiac cycle [24], which is necessary 
to depict any cyclic change in microvascular function in 
the myocardium. For this purpose we divided the car-
diac cycle into 14–17 cardiac phases (depending on the 
heart rates of individual mice) and allowed depicting the 
end-diastole and end-systole separately (Fig. 3a, left). No 
significant differences between males and females were 
found. In D2 females, a higher end diastolic MBF was 
noted compared to D2 males (P < 0.05), but no other sig-
nificant differences were observed (Fig.  3a, right). The 
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Fig. 2 Hypertrophic cardiomyopathy (HCM) mice carrying mybpc3 and myh7 gene variants show myocardial hypertrophy. a Representative FLASH 
cine images (upper row: end‑diastole; lower row: end‑systole) show mid‑ventricular short axis (SAX) views in male B6 (C57BL/6) and D2 (DBA/2J) 
mouse heart acquired at 9.4 T. Yellow lines outline the thickness of left ventricle (LV). White scale bar = 1 mm. b cine‑CMR revealed preserved LV 
function in D2 HCM mice (male: n = 4, female: n = 4) compared to B6 (male n = 4, female n = 4). Functional assessments (LV thickness, LV ejection 
fraction (LVEF), data are shown as mean ± SD) were done on a slice‑by‑slice basis. Endo‑ and epi‑cardiac borders were manually segmented in 
end‑systole and end‑diastole using a stack of short axis FLASH cine images. LVEF were calculated for both sexes. Data are shown as the mean ± SD. 
**p < 0.01, ***p < 0.001 using one‑way ANOVA with Tukey’s multiple‑comparisons test
Fig. 3 Myocardial perfusion deficits in HCM mice. a Representative MBF maps showing end‑diastolic (upper row) and end‑systolic (lower row) 
cardiac phases for a mid‑ventricular SAX views in both male and female control B6 and HCM (D2) mouse heart. MBF maps were acquired using 
cineALS CMR which facilitates the monitoring of dynamic MBF changes in the cardiac cycles. No sex difference in dynamic MBF changes in the 
cardiac cycles was observed between groups (B6 male n = 5, B6 female n = 5, D2 male n = 5, D2 female n = 5). Data are shown as the mean ± SD. 
b Mean MBF were calculated for region of interest (ROI, depicted in orange colour by manually traced endocardial and epicardial contours) in 
mid‑ventricular end‑diastole and end‑systole in all control (B6) and HCM (D2) mice (n = 10 for each group). Data are shown as the mean ± SD. 
**p < 0.01, ***p < 0.001 using one‑way ANOVA with Tukey’s multiple‑comparisons test. (c) Negative Spearman’s rank correlations were seen between 
left ventricular thickness and myocardial blood flow (n = 16)
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resting global myocardial perfusion in the mid-ventricu-
lar slice was lower in D2 than in B6 mice (end-diastole: 
D2  MBFglobal = 7.5 ± 0.6 vs B6  MBFglobal = 9.3 ± 1.6 ml/g/
min, p < 0.05; end-systole: D2  MBFglobal = 6.6 ± 0.8 vs B6 
 MBFglobal = 8.2 ± 2.6  ml/g/min, p < 0.01; Fig.  3b). Blood 
flow to the myocardium occurs mainly during diastole. 
We therefore compared the cyclic changes in blood flow 
in each group. In B6 control mice, the global myocardial 
perfusion did not differ between the end-systolic and 
end-diastolic phases (p = 0.090), whereas in D2 mice 
it was significantly lower in the end-systolic than in the 
end-diastolic phases (p < 0.05; Fig. 3b).
Moreover, there were correlations between the global 
MBF and overall LV wall thickness. A significant nega-
tive correlation was observed between the MBF at rest 
and the correspondent LV thickness, i.e., thicker myo-
cardium was associated with lower myocardial perfusion 
(rho =  − 0.5288; p = 0.0352, non-parametric Spearman 
correlation; Fig. 3c).
Resting myocardial perfusion deficit shows regional 
pattern
Based on the segmentation model (Fig.  4a), we ana-
lysed the regional change of MBF. Septal myocar-
dial perfusion was significantly lower in D2 than in 
B6 mice (end-diastole: D2  MBFseptal = 7.9 ± 1.0 vs B6 
 MBFseptal = 8.9 ± 1.7  ml/g/min, P < 0.01; end-systole: D2 
 MBFseptal = 8.8 ± 1.4 vs B6  MBFseptal = 6.9 ± 1.5  ml/g/
min, p < 0.05; Fig.  4b). The inferior myocardial region 
adjacent to the septum showed lower MBF in D2 than 
in B6 mice (end-diastole: D2  MBFinferior = 9.1 ± 2.2 vs B6 
 MBFinferior = 6.4 ± 0.5 ml/g/min, p < 0.05; end-systole: D2 
 MBFinferior = 8.1 ± 1.4 vs B6  MBFinferior = 5.9 ± 0.6  ml/g/
min, p < 0.05). Lateral and anterior regions did not show 
significant MBF difference.
Detection of impaired microvasculature and fibrosis 
in HCM mice
The factors that might be involved in the reduction of 
small vessel function such as hypertrophy was deter-
mined (Figs.  2 and 3). We further confirmed the thick-
ened LV and myofiber disarray by high resolution in vivo 
and ex vivo CMR in D2 mice (Fig. 5a). It is known that 
small vessels control local blood flow and impact the 
exchange functions of downstream segments of the 
myocardial microcirculation [21]. We therefore deter-
mined whether the small vessel density in the septal and 
inferior myocardium differ in those mice at steady state. 
Immunofluorescence staining for endothelial cells (with 
endothelial cell–specific Isolectin B4) revealed a lower 
number of Isolectin  B4+ vessels in D2 than in B6 mouse 
myocardium (D2 capillary = 31.0 ± 3.8% vs B6 capil-
lary = 40.7 ± 4.6%, p < 0.05; Fig. 5b).
To visualize the myocardial fibrosis precisely, we per-
formed collagen staining to indicate the exact position 
of fibrosis within the LV (Fig. 5c). Myocardial interstitial 
Fig. 4 Quantitative myocardial perfusion at rest. a Schematic illustration of the LV segmentation model for a mid‑ventricular SAX slice of the mice 
heart. b Mean MBF were calculated for interventricular septum for a mid‑ventricular slice during end‑diastole and end‑systole in all control (B6; 
n = 9) and HCM (D2; n = 10) mice. Each dot represents an individual mouse. Data are shown as the mean ± SD. *p < 0.05, **p < 0.01, one‑way ANOVA 
with Tukey’s multiple‑comparisons test
Fig. 5 a Representative long axis view of in vivo (in‑plane spatial resolution = 57 µm) and ex vivo (in‑plane spatial resolution = 30 µm) high 
resolution images showing detailed myocardial structure indicating hypertrophy. Right: A schematic to illustrate the relationship of hypertrophy, 
interstitial fibrosis, perivascular fibrosis and microvasculature. b Representative immunofluorescence staining of mouse heart LV sections for 
Isolectin B4 and the quantification of the capillary density ratio (number/5 imaging area). Scale bar = 50 μm; Data are shown as the mean ± SD 
(n = 3 each sex groups; 6 B6 and 6 D2 mice, respectively). *P < 0.05 (t‑test) c Sirius red staining show interstitial and perivascular collagen deposition. 
Upper row images scale bar = 500 µm; lower row images scale bar = 100 µm. Red arrow depicts perivascular fibrosis and blue arrow depicts 
interstitial fibrosis. Collagen volume fraction (CVF) and perivascular fibrosis ratio (PFR) in septal and inferior area of B6 (n = 8) and D2 (n = 8) mice left 
ventricle. Data are shown as the mean ± SD. **p < 0.01, using t‑test with Mann Whitney test
(See figure on next page.)
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collagen was characterized by the increase in the per-
centage of total LV myocardial tissue occupied by col-
lagen staining. CVF was significantly higher in D2 than 
B6 LV (D2 CVF = 3.7 ± 1.4% vs B6 CVF = 1.7 ± 0.7%, 
p < 0.01). Furthermore, we also observed higher ratio 
of perivascular fibrosis in D2 mice versus B6 mice (D2 
PFR = 2.3 ± 1.0%, B6 PFR = 0.8 ± 0.4%, p < 0.01). Micro-
scopic characteristics revealed the relation of perfusion 
deficit with both perivascular and interstitial fibrosis.
Discussion
In this study, we demonstrate that cine ASL-CMR is 
capable of detecting changes in myocardial perfusion 
that are correlated to a reduction in small vessel density 
in the myocardium. The reduced myocardial perfusion 
provides an indication for microvascular dysfunction in 
HCM. The myocardial perfusion deficiency is correlated 
with LVH and associated with myocardial fibrosis and 
loss of small vessel densities, features which are presum-
ably mediated by the genetic variants commonly found 
in HCM. We analysed the global as well as the regional 
differences of MBF based on the cardiac segmentation 
model. However, motion artefacts have been recognized 
as a limiting factor for the precise detection of myocar-
dial regional differences. These artefacts can be induced 
by myocardial contraction/relaxation, by respiratory 
motion causing a shift a in the chest wall and the dia-
phragm, by susceptibility changes due to motion of the 
heart–lung or heart–liver interface or by non-uniform 
regionally motion patterns (different twist and strain) of 
the heart [35]. Another confounding factor could be the 
different rotational behaviour during early systole in mice 
[31]. The assessment of regional differences in myocar-
dial perfusion pattern has to be further validated with 
respect to their functional component.
Subclinical myocardial remodelling dictates the pro-
gression of HCM, but currently diagnosis and treatment 
of the disease are restricted to measurements of myocar-
dial hypertrophy. Diagnosing microvascular dysfunction 
has been a challenge. Standard tests used to diagnose 
coronary artery disease are not designed to detect small 
vessel disease, so a better understanding of the factors 
associated with microvascular dysfunction and its rela-
tion to the development of HCM would represent a major 
step toward earlier diagnosis and better management of 
the disease. Our results can partially explain previous 
findings showing that HCM patients have lower myocar-
dial blood volume than healthy counterparts [22]. In the 
presence of LVH, effective perfusion is critical to com-
pensate for hypertrophy-induced micro-vessel restric-
tion in the HCM heart. This hypothesis will need to be 
refined, tested and extended to obtain a fuller picture 
of the development of the pathological features of the 
disease and their consequences. In addition, ASL-CMR 
is not a standard clinical technique, while quantitative 
first-pass contrast agent based techniques are clinically 
established for myocardial perfusion imaging. Therefore, 
despite the necessity of bolus injections, robust quantita-
tive first-pass post-processing methods are now becom-
ing more widely available and currently represent the 
method of choice when similar studies are conducted in 
humans. En route to non-contrast myocardial perfusion 
imaging such as ASL-CMR, more studies are needed to 
prove that both methods are equally relevant for clinical 
applications [36].
Although a number of post-mortem studies have dem-
onstrated marked impairment of the coronary microcir-
culation in the absence of significant coronary lesions 
in HCM patients [37, 38], the influence of genetic vari-
ants on microvascular function in HCM myocardium 
has remained unexplored. Measuring myocardial perfu-
sion using CMR or other imaging modalities may reveal 
deficiencies in microvascular function even in mild 
cases or asymptomatic HCM patients, giving it poten-
tial as an independent predictor of clinical outcome [17, 
39]. For instance, many patients with HCM have symp-
toms of myocardial ischemia and cardiac dysfunction. 
Abnormal intramural coronary arteries with markedly 
thickened walls and narrowed lumens are observed in 
HCM patients and may represent a genetic component 
of the underlying myocardial remodelling process [40]. 
Although the clinical relevance of microvascular dys-
function in HCM remains unclear, the fact that intramu-
ral coronary arteries exhibit structural alterations in areas 
of substantial myocardial fibrosis suggests a causal role 
for these arteries in producing ischemia [41]. In line with 
previous findings, we show in this study that the abnor-
mal microvasculature was substantially pronounced in 
the inferior septum. Although it has become evident that 
perivascular fibrosis, but not interstitial fibrosis is asso-
ciated with the impairment of coronary blood flow [42], 
we observed both perivascular and interstitial fibrosis are 
more pronounced in our HCM mouse model. Fibrosis is 
a dynamic process, thus the characterization of temporal 
pattern of both perivascular fibrosis and interstitial fibro-
sis requires additional attention [43].
Classically, HCM is characterized by varying degrees of 
LVH with a preserved or sometimes even increased LVEF 
[44]. Our data suggest that the quantification of cyclic 
changes of myocardial perfusion under resting condi-
tions is sensitive to detect differences in HCM when 
using cineASL-based perfusion CMR. The incidence of 
heart failure (HF) in HCM patients is about ∼50%, with 
symptoms varying from mild to severe [45, 46]. Due to 
a substantial heterogeneity, ascertaining the incidence of 
which HF in HCM is challenging. In HCM, HF has two 
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distinct clinical features: HFpEF or HFrEF. In the major-
ity of HCM patients, HF is manifested as HFpEF phe-
notype, known as “diastolic heart failure” while only a 
minority develops HFrEF at a later stage. A recent large 
cohort study confirmed that systolic dysfunction (mani-
fest by low LVEF) is highly associated with prognosis 
[47]. On the other hand, in HFpEF, microvascular dys-
function was evident as the major determinant of the 
pathological cascade that justifies clinical manifestations 
[48, 49]. Therefore it is extremely relevant to identify 
microvascular dysfunction, including the cause and its 
mechanisms. Recent reports have suggested that patients 
with HFpEF exhibit an increased incidence of small vessel 
disease as shown by abnormal blood flow and increased 
microvascular resistance [49, 50]. Our results support the 
idea that myocardial perfusion changes are connected to 
hypertrophy and the extent of fibrosis and thus can be an 
additional remodelling marker of the HCM phenotype 
regardless of cardiac dysfunction.
Blood flow through small vessels in the myocardium is 
influenced by changes in myocardial tissue pressure dur-
ing heartbeats. Most myocardial perfusion occurs during 
the diastolic heart phase, when the myocardial pressure 
is low [51]. It may also be affected by total capillary den-
sity. Vascular endothelial dysfunction obviously impairs 
myocardial perfusion [52, 53]; our study shows that cap-
illary density is a potential key confounding factor for 
myocardial perfusion.
The accuracy of this non-invasive MBF measurement 
using cineASL has already been validated against the 
more common FAIR Look-Locker Gradient Echo tech-
nique, which was in turn validated against fluorescent 
microspheres [54]. The variations of blood flow through-
out the cardiac cycle under different conditions were 
previously assessed using cineASL [30]. Notably, cyclic 
variation of MBF across the cardiac cycle has been thor-
oughly assessed using this technique in rats [24]. Since 
the MBF value in mice has been shown to be strongly 
dependent on the anesthetic conditions, the relatively 
high values found here could be due to differences in 
anesthesia. The anesthesia is also affected by the individ-
ual experimental conditions: actual isoflurane concentra-
tion inhaled, which is dependent on the face mask, space 
around the animal and gas recovery and therefore diffi-
cult to match across different lab setups. Other influenc-
ing factors are temperature and breathe rate. Therefore, 
one has to be cautious that the results on MBF may not 
reflect perfect resting conditions due to the vasodilating 
effect of isoflurane.
Sex differences are known in several facets of cardiac 
physiology [55]. Sex differences in myocardial perfusion 
have previously been demonstrated in healthy subjects 
and in patients with nonischemic heart failure using 
positron emission tomography (PET) or CMR [56, 57]. 
These reports suggested that females have higher rest-
ing myocardial perfusion compared to males. Our data 
showed the tendency of higher resting MBF in both dias-
tolic and systolic cardiac phases. The sex difference of 
myocardial perfusion will therefore need to be takin into 
account in future studies.
Limitations
While we observed the sex differences in end-diastolic 
MBF in D2 mice but not in other experimental groups, 
this observation might be attributed to the small sample 
size used, which is a recognized limitation of our study. 
We are therefore unable to comment on the exact sex 
influence that might exist with perfusion abnormalities. 
To address this scientific question future work will need 
to incorporate a larger sample size. The cardiac function 
and MBF measurements were not derived from the same 
group of mice. Notably, the physiological effects of anaes-
thesia during CMR have to be minimized. Consequently, 
we have designed the CMR measurement protocol such 
that the total duration of an individual in vivo experiment 
does not exceed a maximum of 60  min. Therefore all 
measurements were performed in the same time window.
We noted that MBF values in mice found in this study 
are higher when compared with published findings [30, 
58, 59]. Notwithstanding our findings remain comparable 
and within the error ranges given in the literature [60]. 
Multiple reasons can contribute to modifications of the 
resting perfusion in rodents such as the level of anes-
thesia, gas mixture or temperature. The comparatively 
high control values have also been obtained by Abdesse-
lam et al. [58], who attributed this to a moderate cardiac 
stress condition due to isoflurane-dependent vasodila-
tion to the elevated baseline values. In previous studies in 
healthy mice using ASL-CMR reported myocardial per-
fusion ranging from 5.0 ± 0.8 to 6.9 ± 1.7  ml/g/min [30, 
59, 61] at 4.7 T and 7.0 ± 0.5 ml/g/min at 7 T [60]. Our 
experiments were performed at 9.4  T and revealed an 
average MBF of 8.2 ± 2.6  ml/g/min, which is in accord-
ance with the literature values. No specific validation 
against gold-standard techniques has been done for per-
fusion measured in this study. However, the employed 
techniques were earlier validated in rats but not mice.
Our study did not tackle the influence of single genetic 
mutations. Therefore, the specific effects of Mybpc3 or 
Myh7 point mutations need to be pursued, as does the 
relation between oxygen consumption and myocardial 
perfusion in HCM.
To tackle the diastolic dysfunction, we did not include 
myocardial strain measurements in our study because 
we would like to first emphasize the early microstruc-
tural change such as vascular deficiency in HCM. MR 
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tagging can be useful for detecting changes in myocardial 
strain in the mouse heart. We anticipate including this 
approach into our future studies. Our preliminary results 
provide the basis for future investigations of the entire 
disease course, including the early disease phase when 
the pathological changes are subtle. Then by performing 
a comprehensive protocol of CMR measurements includ-
ing parametric mapping  (T1,  T2 and  T2*) and ASL, we 
can observe how CMR biomarkers change over time, and 
how these changes can predict later disease outcomes.
Conclusions
We used state-of-the-art in vivo CMR to evaluate micro-
structure and functional changes in mice with HCM 
genetic variants. We have demonstrated that small ves-
sel dysfunction is present in these HCM variants in asso-
ciation with myocardial fibrosis. Our work thus suggests 
that more research on MBF as an imaging marker with 
a potential to monitor early myocardial microvascular 
remodelling is relevant in the field.
Abbreviations
ASL: Arterial spin labelling; Bvf: Fractional tissue blood volume per cardiac 
tissue volume; CMR: Cardiovascular magnetic resonance; Cine ASL‑CMR: 
Dynamic arterial spin labelling based CMR; CVF: Collagen volume fraction; 
ECG: Electrocardiogram; FLASH: Fast low angle shot; FOV: Field‑of‑view; HCM: 
Hypertrophic cardiomyopathy; HFpEF: Heart failure with preserved ejection 
fraction; HFrEF: Heart failure with reduced ejection fraction; LV: Left ventricle/
left ventricular; LVEF: Left ventricular ejection fraction; LVH: Left ventricular 
hypertrophy; MBF: Myocardial blood flow; MYBPC3: Cardiac myosin‑binding 
protein C; MYH7: β‑Myosin‑heavy chain; PFR: Perivascular fibrosis ratio; SAx: 
Short axis; TR: Repetition time; TE: Echo time; SD: Standard deviation.
Acknowledgements
The Helmholtz Association supports open access based upon the ‘’Berlin 
Declaration on Open Access to Knowledge in the Sciences and Humanities’’. 
The authors wish to thank Bernadette Nickl, Thomas Rathjen, Petya Jordan and 
Elena Cano Rincon and Russell Hodge for reagents, fruitful discussions and 
intellectual input.
Authors’ contributions
All authors contributed to the study conception and design. Material prepara‑
tion, data collection and analysis were performed by MCK, YCL and FQ. FK, AP, 
MB, LC and TN have jointly supervised the work. The first draft of the manu‑
script was written by MCK and all authors commented on previous versions of 
the manuscript. All authors read and approved the final manuscript.
Funding
Open Access funding enabled and organized by Projekt DEAL. This work was 
funded in part by the German Centre for Cardiovascular Research (DZHK; BER 
6.1, partner site Berlin) and by the Federal Ministry of Education and Research, 
Berlin, Germany, FKZ 81Z6100161.
Availability of data and materials
The data derived from ASL‑CMR are public and available under https:// figsh 
are. com/ artic les/ figure/ IDL_ images/ 14251 241. Our group is also initiator of 
Open Source MRI (http:// www. opens ource imagi ng. org/). R script for statistical 
analysis of 4 myocardial regions is published on the GitHub (https:// doi. org/ 
10. 5281/ zenodo. 40615 97). Experimental design and data collection were 
handled according to the ARRIVE guidelines (https:// www. nc3rs. org. uk/ sites/ 
defau lt/ files/ docum ents/ Guide lines/ NC3Rs% 20ARR IVE% 20Gui delin es% 20Che 
cklist% 20% 28fil lable% 29. pdf ).
Declarations
Ethics approval and consent to participate
All studies were approved by the Berlin State review board at the ‘’Landesamt 
für Gesundheit und Soziales (LAGeSo)’’. Mice were handled according to the 




The authors declare no conflicting interests in connection with this 
manuscript.
Author details
1 Berlin Ultrahigh Field Facility (B.U.F.F.), Max Delbrück Center for Molecular 
Medicine in the Helmholtz Association (MDC), Robert‑Rössle Strasse 10, 
13125 Berlin, Germany. 2 DZHK (German Centre for Cardiovascular Research), 
Partner site Berlin, Berlin, Germany. 3 Centre de Résonance Magnétique 
Biologique et Médicale (CRMBM), Aix‑Marseille University, CNRS, Marseille, 
France. 4 Molecular Biology of Peptide Hormones, Max Delbrück Center 
for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany. 
5 Department of Experimental Pharmacology and Toxicology, University 
Medical Center Hamburg‑Eppendorf, Hamburg, Germany. 6 DZHK (German 
Centre for Cardiovascular Research), Partner site Hamburg/Kiel/Lübeck, Berlin, 
Germany. 7 Experimental and Clinical Research Center (ECRC), A Joint Coop‑
eration between the Charité Medical Faculty and the Max‑Delbrück Center 
for Molecular Medicine, Berlin, Germany. 
Received: 6 January 2020   Accepted: 6 April 2021
References
 1. Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on 
the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 
2015;65(12):1249–54.
 2. Franz WM, Muller OJ, Katus HA. Cardiomyopathies: from genetics to the 
prospect of treatment. Lancet. 2001;358(9293):1627–37.
 3. Bagnall RD, Weintraub RG, Ingles J, Duflou J, Yeates L, Lam L, Davis AM, 
Thompson T, Connell V, Wallace J, et al. A prospective study of sud‑
den cardiac death among children and young adults. N Engl J Med. 
2016;374(25):2441–52.
 4. Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. Sudden deaths in 
young competitive athletes: analysis of 1866 deaths in the United States, 
1980–2006. Circulation. 2009;119(8):1085–92.
 5. Michels M, Soliman OI, Phefferkorn J, Hoedemaekers YM, Kofflard MJ, 
Dooijes D, Majoor‑Krakauer D, Ten Cate FJ. Disease penetrance and risk 
stratification for sudden cardiac death in asymptomatic hypertrophic 
cardiomyopathy mutation carriers. Eur Heart J. 2009;30(21):2593–8.
 6. Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet. 
2013;381(9862):242–55.
 7. Ingles J, Goldstein J, Thaxton C, Caleshu C, Corty EW, Crowley SB, Dough‑
erty K, Harrison SM, McGlaughon J, Milko LV, et al. Evaluating the clinical 
validity of hypertrophic cardiomyopathy genes. Circ Genom Precis Med. 
2019;12(2):e002460.
 8. Toepfer CN, Wakimoto H, Garfinkel AC, McDonough B, Liao D, Jiang J, Tai 
AC, Gorham JM, Lunde IG, Lun M, et al. Hypertrophic cardiomyopathy 
mutations in MYBPC3 dysregulate myosin. Sci Transl Med. 2019. https:// 
doi. org/ 10. 1126/ scitr anslm ed. aat11 99.
 9. Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS. Hyper‑
trophic cardiomyopathy: present and future, with translation into con‑
temporary cardiovascular medicine. J Am Coll Cardiol. 2014;64(1):83–99.
 10. Burchfield JS, Xie M, Hill JA. Pathological ventricular remodeling: mecha‑
nisms: part 1 of 2. Circulation. 2013;128(4):388–400.
 11. Hayashi M, Shimizu W, Albert CM. The spectrum of epidemiology under‑
lying sudden cardiac death. Circ Res. 2015;116(12):1887–906.
Page 12 of 13Ku et al. J Cardiovasc Magn Reson           (2021) 23:63 
 12. Weissler‑Snir A, Adler A, Williams L, Gruner C, Rakowski H. Prevention of 
sudden death in hypertrophic cardiomyopathy: bridging the gaps in 
knowledge. Eur Heart J. 2017;38(22):1728–37.
 13. Maron BJ. Clinical course and management of hypertrophic cardiomyo‑
pathy. N Engl J Med. 2018;379(7):655–68.
 14. Soler R, Mendez C, Rodriguez E, Barriales R, Ochoa JP, Monserrat L. Phe‑
notypes of hypertrophic cardiomyopathy. An illustrative review of MRI 
findings. Insights Imaging. 2018;9(6):1007–20.
 15. Raman B, Ariga R, Spartera M, Sivalokanathan S, Chan K, Dass S, Petersen 
SE, Daniels MJ, Francis J, Smillie R, et al. Progression of myocardial fibrosis 
in hypertrophic cardiomyopathy: mechanisms and clinical implications. 
Eur Heart J Cardiovasc Imaging. 2019;20(2):157–67.
 16. Petersen SE, Jerosch‑Herold M, Hudsmith LE, Robson MD, Francis 
JM, Doll HA, Selvanayagam JB, Neubauer S, Watkins H. Evidence for 
microvascular dysfunction in hypertrophic cardiomyopathy: new 
insights from multiparametric magnetic resonance imaging. Circulation. 
2007;115(18):2418–25.
 17. Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici PG. Coronary 
microvascular dysfunction and prognosis in hypertrophic cardiomyopa‑
thy. N Engl J Med. 2003;349(11):1027–35.
 18. Timmer SA, Knaapen P. Coronary microvascular function, myocardial 
metabolism, and energetics in hypertrophic cardiomyopathy: insights 
from positron emission tomography. Eur Heart J Cardiovasc Imaging. 
2013;14(2):95–101.
 19. Rosen BD, Lima JA, Nasir K, Edvardsen T, Folsom AR, Lai S, Bluemke 
DA, Jerosch‑Herold M. Lower myocardial perfusion reserve is associ‑
ated with decreased regional left ventricular function in asymptomatic 
participants of the multi‑ethnic study of atherosclerosis. Circulation. 
2006;114(4):289–97.
 20. Duncker DJ, Koller A, Merkus D, Canty JM Jr. Regulation of coronary 
blood flow in health and ischemic heart disease. Prog Cardiovasc Dis. 
2015;57(5):409–22.
 21. Jacob M, Chappell D, Becker BF. Regulation of blood flow and volume 
exchange across the microcirculation. Crit Care. 2016;20(1):319.
 22. Huelnhagen T, Ku MC, Reimann HM, Serradas Duarte T, Pohlmann A, 
Flemming B, Seeliger E, Eichhorn C, Ferrari VA, Prothmann M, et al. Myo‑
cardial effective transverse relaxation time T 2(*) is elevated in hyper‑
trophic cardiomyopathy: A 7.0 T magnetic resonance imaging study. Sci 
Rep. 2018;8(1):3974.
 23. Huelnhagen T, Hezel F, Serradas Duarte T, Pohlmann A, Oezerdem C, 
Flemming B, Seeliger E, Prothmann M, Schulz‑Menger J, Niendorf T. 
Myocardial effective transverse relaxation time T2* Correlates with 
left ventricular wall thickness: a 7.0 T MRI study. Magn Reson Med. 
2017;77(6):2381–9.
 24. Troalen T, Capron T, Bernard M, Kober F. In vivo characterization of rodent 
cyclic myocardial perfusion variation at rest and during adenosine‑
induced stress using cine‑ASL cardiovascular magnetic resonance. J 
Cardiovasc Magn Reson. 2014;16:18.
 25. Kober F, Jao T, Troalen T, Nayak KS. Myocardial arterial spin labeling. J 
Cardiovasc Magn Reson. 2016;18:22.
 26. Naresh NK, Chen X, Moran E, Tian Y, French BA, Epstein FH. Repeatability 
and variability of myocardial perfusion imaging techniques in mice: 
Comparison of arterial spin labeling and first‑pass contrast‑enhanced 
MRI. Magn Reson Med. 2016;75(6):2394–405.
 27. Thomson KL, Ormondroyd E, Harper AR, Dent T, McGuire K, Baksi J, 
Blair E, Brennan P, Buchan R, Bueser T, et al. Analysis of 51 proposed 
hypertrophic cardiomyopathy genes from genome sequencing data in 
sarcomere negative cases has negligible diagnostic yield. Genet Med. 
2019;21(7):1576–84.
 28. Zhao W, Zhao T, Chen Y, Zhao F, Gu Q, Williams RW, Bhattacharya SK, Lu L, 
Sun Y. A Murine Hypertrophic Cardiomyopathy Model: The DBA/2J Strain. 
PLoS ONE. 2015;10(8):e0133132.
 29. Ku MC, Huelnhagen T, Niendorf T, Pohlmann A. Cardiac MRI in Small 
Animals. Methods Mol Biol. 2018;1718:269–84.
 30. Troalen T, Capron T, Cozzone PJ, Bernard M, Kober F. Cine‑ASL: a steady‑
pulsed arterial spin labeling method for myocardial perfusion mapping in 
mice. Part I. Experimental study. Magn Reson Med. 2013;70(5):1389–98.
 31. Jung B, Odening KE, Dall’Armellina E, Foll D, Menza M, Markl M, Schneider 
JE. A quantitative comparison of regional myocardial motion in mice, rab‑
bits and humans using in‑vivo phase contrast CMR. J Cardiovasc Magn 
Reson. 2012;14:87.
 32. Ide S, Riesenkampff E, Chiasson DA, Dipchand AI, Kantor PF, Chaturvedi 
RR, Yoo SJ, Grosse‑Wortmann L. Histological validation of cardiovascular 
magnetic resonance T1 mapping markers of myocardial fibrosis in paedi‑
atric heart transplant recipients. J Cardiovasc Magn Reson. 2017;19(1):10.
 33. Rikitake Y, Oyama N, Wang CY, Noma K, Satoh M, Kim HH, Liao JK. 
Decreased perivascular fibrosis but not cardiac hypertrophy in ROCK1+/‑ 
haploinsufficient mice. Circulation. 2005;112(19):2959–65.
 34. Morita H, Rehm HL, Menesses A, McDonough B, Roberts AE, Kucherlapati 
R, Towbin JA, Seidman JG, Seidman CE. Shared genetic causes of cardiac 
hypertrophy in children and adults. N Engl J Med. 2008;358(18):1899–908.
 35. Del‑Canto I, Lopez‑Lereu MP, Monmeneu JV, Croisille P, Clarysse P, Chorro 
FJ, Bodi V, Moratal D. Characterization of normal regional myocardial func‑
tion by MRI cardiac tagging. J Magn Reson Imaging. 2015;41(1):83–92.
 36. Do HP, Ramanan V, Qi X, Barry J, Wright GA, Ghugre NR, Nayak KS. Non‑
contrast assessment of microvascular integrity using arterial spin labeled 
cardiovascular magnetic resonance in a porcine model of acute myocar‑
dial infarction. J Cardiovasc Magn Reson. 2018;20(1):45.
 37. Basso C, Thiene G, Corrado D, Buja G, Melacini P, Nava A. Hypertrophic 
cardiomyopathy and sudden death in the young: pathologic evidence of 
myocardial ischemia. Hum Pathol. 2000;31(8):988–98.
 38. Galati G, Leone O, Pasquale F, Olivotto I, Biagini E, Grigioni F, Pilato E, 
Lorenzini M, Corti B, Foa A, et al. Histological and histometric characteri‑
zation of myocardial fibrosis in end‑stage hypertrophic cardiomyopathy: 
a clinical‑pathological study of 30 explanted hearts. Circ Heart Fail. 2016. 
https:// doi. org/ 10. 1161/ CIRCH EARTF AILURE. 116. 003090.
 39. Villemain O, Correia M, Mousseaux E, Baranger J, Zarka S, Podetti I, Soulat 
G, Damy T, Hagege A, Tanter M, et al. Myocardial stiffness evaluation using 
noninvasive shear wave imaging in healthy and hypertrophic cardiomyo‑
pathic adults. JACC Cardiovasc Imaging. 2019;12(7 Pt 1):1135–45.
 40. Maron BJ, Wolfson JK, Epstein SE, Roberts WC. Intramural (“small vessel”) 
coronary artery disease in hypertrophic cardiomyopathy. J Am Coll 
Cardiol. 1986;8(3):545–57.
 41. Camaioni C, Knott KD, Augusto JB, Seraphim A, Rosmini S, Ricci F, Bou‑
bertakh R, Xue H, Hughes R, Captur G, et al. Inline perfusion mapping 
provides insights into the disease mechanism in hypertrophic cardio‑
myopathy. Heart. 2020;106(11):824–9.
 42. Dai Z, Aoki T, Fukumoto Y, Shimokawa H. Coronary perivascular fibrosis is 
associated with impairment of coronary blood flow in patients with non‑
ischemic heart failure. J Cardiol. 2012;60(5):416–21.
 43. de Boer RA, De Keulenaer G, Bauersachs J, Brutsaert D, Cleland JG, Diez 
J, Du XJ, Ford P, Heinzel FR, Lipson KE, et al. Towards better definition, 
quantification and treatment of fibrosis in heart failure. A scientific 
roadmap by the Committee of Translational Research of the Heart Failure 
Association (HFA) of the European Society of Cardiology. Eur J Heart Fail. 
2019;21(3):272–85.
 44. Lam CSP, Voors AA, de Boer RA, Solomon SD, van Veldhuisen DJ. Heart 
failure with preserved ejection fraction: from mechanisms to therapies. 
Eur Heart J. 2018;39(30):2780–92.
 45. Seferovic PM, Polovina M, Bauersachs J, Arad M, Gal TB, Lund LH, Felix SB, 
Arbustini E, Caforio ALP, Farmakis D, et al. Heart failure in cardiomyopa‑
thies: a position paper from the Heart Failure Association of the European 
Society of Cardiology. Eur J Heart Fail. 2019;21(5):553–76.
 46. Maron BJ, Rowin EJ, Casey SA, Link MS, Lesser JR, Chan RH, Garberich RF, 
Udelson JE, Maron MS. Hypertrophic cardiomyopathy in adulthood asso‑
ciated with low cardiovascular mortality with contemporary manage‑
ment strategies. J Am Coll Cardiol. 2015;65(18):1915–28.
 47. Marstrand P, Han L, Day SM, Olivotto I, Ashley EA, Michels M, Pereira AC, 
Wittekind SG, Helms A, Saberi S, et al. Hypertrophic cardiomyopathy with 
left ventricular systolic dysfunction: insights from the SHaRe registry. 
Circulation. 2020;141(17):1371–83.
 48. Crea F, Bairey Merz CN, Beltrame JF, Kaski JC, Ogawa H, Ong P, Sechtem 
U, Shimokawa H, Camici PG, Coronary Vasomotion Disorders Interna‑
tional Study Group. The parallel tales of microvascular angina and heart 
failure with preserved ejection fraction: a paradigm shift. Eur Heart J. 
2017;38(7):473–7.
 49. D’Amario D, Migliaro S, Borovac JA, Restivo A, Vergallo R, Galli M, Leone 
AM, Montone RA, Niccoli G, Aspromonte N, et al. Microvascular dysfunc‑
tion in heart failure with preserved ejection fraction. Front Physiol. 
2019;10:1347.
 50. Joung S, Wei J, Nelson MD, Aldiwani H, Shufelt C, Tamarappoo B, Berman 
D, Thomson LEJ, Bairey Merz CN. Progression of coronary microvascular 
Page 13 of 13Ku et al. J Cardiovasc Magn Reson           (2021) 23:63  
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
dysfunction to heart failure with preserved ejection fraction: a case 
report. J Med Case Rep. 2019;13(1):134.
 51. Goodwill AG, Dick GM, Kiel AM, Tune JD. Regulation of coronary blood 
flow. Compr Physiol. 2017;7(2):321–82.
 52. Marti CN, Gheorghiade M, Kalogeropoulos AP, Georgiopoulou VV, 
Quyyumi AA, Butler J. Endothelial dysfunction, arterial stiffness, and heart 
failure. J Am Coll Cardiol. 2012;60(16):1455–69.
 53. Fernlund E, Gyllenhammar T, Jablonowski R, Carlsson M, Larsson A, Arnlov 
J, Liuba P. Serum biomarkers of myocardial remodeling and coronary 
dysfunction in early stages of hypertrophic cardiomyopathy in the young. 
Pediatr Cardiol. 2017;38(4):853–63.
 54. Jacquier A, Kober F, Bun S, Giorgi R, Cozzone PJ, Bernard M. Quantifica‑
tion of myocardial blood flow and flow reserve in rats using arterial spin 
labeling MRI: comparison with a fluorescent microsphere technique. 
NMR Biomed. 2011;24(9):1047–53.
 55. Mauvais‑Jarvis F, Bairey Merz N, Barnes PJ, Brinton RD, Carrero JJ, 
DeMeo DL, De Vries GJ, Epperson CN, Govindan R, Klein SL, et al. 
Sex and gender: modifiers of health, disease, and medicine. Lancet. 
2020;396(10250):565–82.
 56. Kadkhodayan A, Lin CH, Coggan AR, Kisrieva‑Ware Z, Schecht‑
man KB, Novak E, Joseph SM, Davila‑Roman VG, Gropler RJ, Dence 
C, et al. Sex affects myocardial blood flow and fatty acid substrate 
metabolism in humans with nonischemic heart failure. J Nucl Cardiol. 
2017;24(4):1226–35.
 57. Nickander J, Themudo R, Sigfridsson A, Xue H, Kellman P, Ugander M. 
Females have higher myocardial perfusion, blood volume and extracel‑
lular volume compared to males—an adenosine stress cardiovascular 
magnetic resonance study. Sci Rep. 2020;10(1):10380.
 58. Abdesselam I, Pepino P, Troalen T, Macia M, Ancel P, Masi B, Fourny N, 
Gaborit B, Giannesini B, Kober F, et al. Time course of cardiometabolic 
alterations in a high fat high sucrose diet mice model and improvement 
after GLP‑1 analog treatment using multimodal cardiovascular magnetic 
resonance. J Cardiovasc Magn Reson. 2015;17:95.
 59. Vandsburger MH, French BA, Helm PA, Roy RJ, Kramer CM, Young AA, 
Epstein FH. Multi‑parameter in vivo cardiac magnetic resonance imaging 
demonstrates normal perfusion reserve despite severely attenuated 
beta‑adrenergic functional response in neuronal nitric oxide synthase 
knockout mice. Eur Heart J. 2007;28(22):2792–8.
 60. Streif JU, Nahrendorf M, Hiller KH, Waller C, Wiesmann F, Rommel E, Haase 
A, Bauer WR. In vivo assessment of absolute perfusion and intracapillary 
blood volume in the murine myocardium by spin labeling magnetic 
resonance imaging. Magn Reson Med. 2005;53(3):584–92.
 61. Kober F, Iltis I, Cozzone PJ, Bernard M. Myocardial blood flow mapping in 
mice using high‑resolution spin labeling magnetic resonance imaging: 
influence of ketamine/xylazine and isoflurane anesthesia. Magn Reson 
Med. 2005;53(3):601–6.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub‑
lished maps and institutional affiliations.
